In analogous works in high-risk neuroblastoma, molecularly selected patients are treated in an ongoing study with the ALK inhibitor ceritinib combined with the CDK4/6 inhibitor ribociclib based on preclinical evidence of synergy (NCT02780128, Table 2) [115]. The gene discussed is ALK; the disease is neuroblastoma.